Shi Yuru, Hu Miaomiao, Wu Jing, Liu Ting, Qi Yingjie, Li Ang
Department of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China (Hefei Infectious Disease Hospital), Hefei, Anhui, 230000, China.
Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Dian Diagnostics Group Co., Ltd, Hangzhou, Zhejiang, 310030, China.
BMC Infect Dis. 2025 May 6;25(1):666. doi: 10.1186/s12879-025-10995-3.
This study aims to examine the potential link between incomplete immune reconstitution following ART treatment and gut microbiota dysbiosis.
We collected clinical data and fecal samples from 50 HIV patients undergoing ART and 30 untreated patients. Based on the observed immune function reconstruction, we further categorized the ART(+) group into a responder group (n = 30) and a non-responder group (n = 20). The gut microbiota composition differences were assessed using Alpha diversity and Beta diversity analysis, while differential genera were identified through linear discriminant analysis effect size (LEfSe). Subsequently, functional disparities in the gut microbiota were investigated using PICRUSt2 and metagenomeSeq software.
The results of Alpha diversity and Beta diversity revealed significant differences in the composition of gut microbiota among the three groups. Differential genus analysis identified Morganella as an exclusive genus present only in the Non-responder group, exhibiting a significantly higher relative abundance. Correlation analysis demonstrated a positive association between Morganella and LDL levels. The CAZY analysis revealed that glycosyltransferase 25 (GT25) was significantly expressed in the Non-responder group, whereas it was either undetectable or exhibited extremely low expression levels in both the Responder group and the ART(-) group. Importantly, the correlation analysis indicated a positive association between Morganella and GT25 secretion.
The ecological imbalance of Morganella might be associated with incomplete immune reconstitution following ART, potentially mediated by GT25 secretions. Consequently, Morganella could serve as a promising biomarker for predicting incomplete immune reconstitution in AIDS patients undergoing ART.
本研究旨在探讨抗逆转录病毒疗法（ART）治疗后免疫重建不完全与肠道微生物群失调之间的潜在联系。
我们收集了50例接受ART治疗的HIV患者和30例未接受治疗患者的临床数据和粪便样本。根据观察到的免疫功能重建情况，我们将ART（+）组进一步分为反应者组（n = 30）和无反应者组（n = 20）。使用Alpha多样性和Beta多样性分析评估肠道微生物群组成差异，同时通过线性判别分析效应大小（LEfSe）确定差异菌属。随后，使用PICRUSt2和宏基因组测序软件研究肠道微生物群的功能差异。
Alpha多样性和Beta多样性结果显示，三组之间肠道微生物群组成存在显著差异。差异菌属分析确定摩根氏菌是仅存在于无反应者组中的唯一菌属，其相对丰度显著更高。相关性分析表明摩根氏菌与低密度脂蛋白水平呈正相关。碳水化合物活性酶（CAZY）分析显示，糖基转移酶25（GT25）在无反应者组中显著表达，而在反应者组和ART（-）组中均未检测到或表达水平极低。重要的是，相关性分析表明摩根氏菌与GT25分泌呈正相关。
摩根氏菌的生态失衡可能与ART治疗后免疫重建不完全有关，可能由GT25分泌介导。因此，摩根氏菌可作为预测接受ART治疗的艾滋病患者免疫重建不完全的有前景的生物标志物。
